Spark Therapeutics Inc. (NASDAQ:ONCE) shares traded down 1.7% on Monday . The stock traded as low as $54.42 and last traded at $54.47, with a volume of 409,327 shares traded. The stock had previously closed at $55.43.

A number of analysts recently commented on ONCE shares. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $94.00 target price (down from $100.00) on shares of Spark Therapeutics in a research report on Thursday, June 23rd. SunTrust Banks Inc. boosted their target price on Spark Therapeutics from $64.00 to $72.00 and gave the company a “buy” rating in a research report on Tuesday, June 21st. Jefferies Group reaffirmed a “hold” rating on shares of Spark Therapeutics in a research report on Sunday, June 12th. Wedbush reaffirmed an “underperform” rating and issued a $29.00 target price on shares of Spark Therapeutics in a research report on Monday, June 13th. Finally, Cowen and Company reaffirmed a “buy” rating and issued a $75.00 target price on shares of Spark Therapeutics in a research report on Thursday, May 19th. Three equities research analysts have rated the stock with a sell rating, four have issued a hold rating and six have issued a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $58.56.

The firm has a 50-day moving average price of $51.55 and a 200 day moving average price of $38.24. The firm’s market cap is $1.49 billion.

Spark Therapeutics (NASDAQ:ONCE) last issued its quarterly earnings results on Wednesday, May 4th. The company reported ($0.95) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.84) by $0.11. The firm had revenue of $1.29 million for the quarter, compared to analyst estimates of $1.48 million. The business’s revenue was down 43.2% on a year-over-year basis. Analysts forecast that Spark Therapeutics Inc. will post ($3.92) earnings per share for the current fiscal year.

In other news, insider Coelho Rogerio Vivaldi sold 7,000 shares of Spark Therapeutics stock in a transaction on Thursday, April 21st. The shares were sold at an average price of $40.02, for a total transaction of $280,140.00. Following the transaction, the insider now owns 19,716 shares in the company, valued at approximately $789,034.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Anand Mehra sold 500 shares of Spark Therapeutics stock in a transaction on Tuesday, May 31st. The stock was sold at an average price of $60.00, for a total transaction of $30,000.00. The disclosure for this sale can be found here.

Other hedge funds and institutional investors have modified their holdings of the company. Casdin Capital LLC acquired a new position in shares of Spark Therapeutics during the fourth quarter valued at $6,570,000. UBS Oconnor LLC purchased a new position in Spark Therapeutics during the fourth quarter worth $4,395,000. TD Asset Management Inc. boosted its position in Spark Therapeutics by 72.2% in the fourth quarter. TD Asset Management Inc. now owns 58,187 shares of the company’s stock worth $2,636,000 after buying an additional 24,400 shares during the period. Finally, CAM Group Holding A S boosted its position in Spark Therapeutics by 1.8% in the fourth quarter. CAM Group Holding A S now owns 78,620 shares of the company’s stock worth $3,562,000 after buying an additional 1,400 shares during the period.

Spark Therapeutics, Inc (Spark) is engaged in developing products in the field of gene therapy. Spark’s product candidate, SPK-RPE65, which is in Phase III clinical trial stage, targets a group of rare blinding conditions known as inherited retinal dystrophies (IRDs), caused by non-sex linked or autosomal recessive mutations in the RPE65 gene.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.